NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Artelo Biosciences, Inc. (ARTL) Stock Analysis

Artelo Biosciences, Inc. (ARTL) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ARTL

$6.04

−$0.18 (−2.89%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ARTL with… →

ARTL Key Statistics

As of Sep 4, 2026
Trading
Open
$6.25
Previous Close
$6.22
Day's Range
5.92–6.35
52-Week Range
4.68–179.19
Volume
27.80K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.07
Valuation
Market Cap
$3.31M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−95.29
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$12.88M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
547.77K
1-Year Return
−53.72%
Dividend and dates
Avg Volume
51.51K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ARTL Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+65.03%
2025−80.82%
2024−24.29%
2023−51.56%
2022−62.88%
2021−28.90%
2020−72.96%
2019 (partial year)−41.94%

As of September 4, 2026.

ARTL Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$12.88M—
2024$0.00−$9.83M—
2023$0.00−$9.29M—
2022$0.00−$10.08M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$11.40M−$12.88M—
2024$0.00—−$10.11M−$9.83M—
2023$0.00—−$9.93M−$9.29M—
2022$0.00—−$10.29M−$10.08M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ARTL Valuation vs Biotechnology Median

Median of 656 stocks
MetricARTLBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Artelo Biosciences, Inc. (ARTL) at $3.31M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 7 employees.

Over the past 52 weeks the price has ranged from $4.68 to $179.19. The most recent close on file for ARTL is $6.04, dated September 4, 2026. That is −$0.18 (−2.89%) against the previous close. The latest close sits 29.06% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $12.88M. The reported profit margin is 0%. Trailing earnings per share are −95.29.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Beta against the wider market is reported at −0.08. Annualized volatility over the trailing 7 years is 336.03%. Over the trailing twelve months the price has returned −53.72%. Measured over 5 years, that is −52.40% a year compounded.

Growth & Income

No dividend is on file for ARTL.

Across the complete calendar years on file, 2024 returned −24.29% and 2025 returned −80.82%. Of the 6 complete calendar years on file, 0 finished higher. 2026 is still running; the price is +65.03% year to date.

Peer Comparison

Artelo Biosciences, Inc. (ARTL) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Artelo Biosciences, Inc. ARTL $3.31M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Artelo Biosciences, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Artelo Biosciences, Inc.

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications. It also offers ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Visit website →